HC Wainwright Reaffirms Buy Rating for Immunocore (NASDAQ:IMCR)

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock.

Several other research analysts have also commented on the stock. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Trading Up 1.9 %

Shares of IMCR stock opened at $28.80 on Wednesday. The company has a 50-day moving average of $30.08 and a two-hundred day moving average of $31.38. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 1-year low of $27.19 and a 1-year high of $66.00. The firm has a market cap of $1.44 billion, a PE ratio of -30.32 and a beta of 0.79.

Institutional Trading of Immunocore

Hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Immunocore in the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC acquired a new stake in Immunocore during the fourth quarter worth approximately $330,000. Finally, Virtus ETF Advisers LLC raised its holdings in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after purchasing an additional 3,238 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.